regulatory
confidence high
sentiment negative
materiality 0.75
Inhibikase receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule
Inhibikase Therapeutics, Inc.
- Nasdaq notice dated July 25, 2022; stock bid price below $1.00 for 30 consecutive business days.
- Company has 180 calendar days, until January 23, 2023, to regain compliance.
- To cure, closing bid price must be at least $1.00 for 10 consecutive business days.
- Failure may lead to a second 180-day cure period or delisting, subject to appeal.